A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 in Patients with Advanced Solid Tumor Malignancies
Details
Age
Adult
Eligibility
ESCALATION: tissue agnostic EXPANSION: panc, lung, colon w/ RAS mutation and glioblastoma (w or w/o mutations )
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Wells Messersmith, MD
Study ID
Protocol Number: 20-3038
More information available at ClinicalTrials.gov: NCT04678648
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers